


L4 – Quantitative Evaluation of Binding Interactions



February 20, 2020

Molecular recognition is ubiquitous in biology



proteins, lipids, sugars, nucleic acids, metabolites, antibodies

The Inner Life of the Cell – Dr. Alain Viel, Harvard



<https://www.youtube.com/watch?v=FzcTgrxMzZk>

8 minute video – watch it while you are running an experiment

Basic language of binding interactions


from 20.110

Affinity: strength of the interaction, measured by the corresponding decrease in free energy upon binding

Specificity: relative strength of interaction for a 'cognate' and 'non-cognate' receptor-ligand complex

There are two basic types of non-covalent interactions: simple binding and allosteric


Some binding interactions are '*simple*' equilibria – each encounter is independent



There are two basic types of non-covalent interactions: simple binding and allosteric


Some binding interactions are 'simple' equilibria – each encounter is independent

simple interaction



Others are more complex, involving *allostery*, where one ligand binding event alters the affinity for another ligand

allosteric interaction




Thermodynamic analyses provide insight into molecular interactions

As you learned in 20.110, we can think about the following binding-related terms thermodynamically:

- affinity and specificity
- contribution of entropy and enthalpy
- dependence on temperature
- contributions of chemical groups on the ligand and/or the receptor

This information can in turn be used to understand a system and to alter the system (e.g. drug design)

Relationship of ligand binding free energy to association constants



From 20.110:


$$\Delta G_{bind}^{\circ} = -RT \ln K_A$$

$$K_D = \frac{[P][L]}{[P \cdot L]} = \frac{1}{K_A}$$

(dissociation constant)

$$\Delta G_{bind}^{\circ} = + RT \ln K_D$$

Relationship of ligand binding free energy to association constants



From 20.110:

$$\Delta G_{\text{bind}}^{\circ} = -RT \ln K_A$$




$$K_D = \frac{[P][L]}{[P \cdot L]} = \frac{1}{K_A}$$

(dissociation constant)

$$\Delta G_{\text{bind}}^{\circ} = + RT \ln K_D$$

Binding isotherms are half maximal at
 $[L] = K_D$


'binding isotherm plot'



intermediate ligand concentration: $f = 0.5$
 $K_D = [L]$ when $f = 0.5$

steady-state
equilibrium analysis

Logarithmic vs. Linear display of data



as a corollary, choose your concentrations wisely:

1, 3, 10, 30, 100, 300 nM

vs.

50, 100, 150, 200, 250, 300 nM

Range of biologically important interactions


Type of Interaction	K_D (molar)	ΔG_{bind}^0 (at 300K) kcal/mol
Enzyme:ATP	$\sim 1 \times 10^{-3}$ to $\sim 1 \times 10^{-6}$ (millimolar to micromolar)	-4 to -8 kcal/mol
signaling protein binding to a target	$\sim 1 \times 10^{-6}$ (micromolar)	-8 kcal/mol
Sequence-specific recognition of DNA by a transcription factor	$\sim 1 \times 10^{-9}$ (nanomolar)	-12 kcal/mol
small molecule inhibitors of proteins (drugs)	$\sim 1 \times 10^{-9}$ to $\sim 1 \times 10^{-12}$ (nanomolar to picomolar)	-12 to -17 kcal/mol
biotin binding to avidin protein (strongest known non-covalent interaction)	$\sim 1 \times 10^{-15}$ (femtomolar)	-21 kcal/mol

higher K_D value
weaker interaction

lower K_D value
stronger interaction

Specificity in molecular recognition


discrimination among targets



Proteinase K

low specificity

Aliphatic/X
Aromatic/X




Tobacco Etch Virus (TEV) protease

high specificity

Glu-X-X-Tyr-X-Gln/Ser


Specificity in molecular recognition – kinase drugs



AC220




CEP-701




MLN-518


binding constants



PKC-412



CGP-52421




Sorafenib



Sunitinib


Specificity in drug binding – fractional saturation

deliver the drug at a concentration below the K_D for non-cognate target




Specificity in drug binding – fractional saturation

deliver the drug at a concentration below the TD_{50} in patients



impact therapeutic effects?




ED_{50} = effective in 50% patients


TD_{50} = toxic in 50% patients

But how do we go about measuring these K_D values in a laboratory setting?


Methods to evaluate binding interactions




Methods to evaluate binding interactions



Measuring a thermal melt profile for a protein




Dyes used to detect protein unfolding



ANS


8-anilinonaphthalene-1-sulfonic acid
(1965)

Dyes used to detect protein unfolding



ANS

8-anilino-naphthalene-1-sulfonic acid
(1965)



Nile Red


9-diethylamino-5-benzo[a]phenoxazinone
(1985)



solvatochromic


Nile Red under visible and
UV light in different solvents

Dyes used to detect protein unfolding



ANS

8-anilino-1-naphthalene-sulfonic acid
(1965)




Nile Red

9-diethylamino-5-benzo[a]phenoxazinone
(1985)



solvatochromic

Nile Red under visible and
UV light in different solvents




SYPRO® Orange

Most common dye for DSF/TS
(2004)


binds nonspecifically to hydrophobic surfaces;
water quenches fluorescence

Dyes used to detect protein unfolding



ANS

8-anilino-1-naphthalene-sulfonic acid
(1965)




Nile Red

9-diethylamino-5-benzo[a]phenoxazinone
(1985)



solvatochromic


Nile Red under visible and UV light in different solvents



SYPRO® Orange

Most common dye for DSF/TS
(2004)

binds nonspecifically to hydrophobic surfaces;
water quenches fluorescence




CPM


N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide
(2008)

only fluoresces after reacting with Cys residues


What happens when you add a small molecule?



Thermal shift assays with small molecules




Real thermal shift screens with small molecules



preferential ligand binding to unfolded states?

Real results from thermal shift studies


assay development




consider optimizing buffer conditions – pH, cofactors

Real results with thermal shift assays

three replicates for a single experiment




raw fluorescence thermal curves




first derivative representation

Real results with thermal shift assays





raw fluorescence thermal curves

Protein disorder continuum




Protein disorder continuum



Determining apparent dissociation constants

hexokinase (receptor) and glucose (ligand)




Experiment 1:

test a wide range of glucose concentrations

K_D is likely between 0.2 and 1.7 mM

Determining apparent dissociation constants


hexokinase (receptor) and glucose (ligand)



Experiment 1:

test a wide range of glucose concentrations

K_D is likely between 0.2 and 1.7 mM




Experiment 2:

test 16 concentration of glucose
fit to single binding event model (red)

apparent $K_D \sim 1.12 \pm 0.05$ mM


Small molecule stabilizers to aid crystallization

improving structural biology efforts




Small molecule stabilizers to aid crystallization

improving structural biology efforts



Stage 1: preliminary screening



Differential scanning fluorimetry




Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination

Masoud Vedadi*, Frank H. Niesen†, Abdellah Allali-Hassani*, Oleg Y. Fedorov†, Patrick J. Finerty, Jr.*, Gregory A. Wasney*, Ron Yeung*, Cheryl Arrowsmith*, Linda J. Ball†, Helena Berglund‡, Raymond Hul*, Brian D. Marsden†, Pär Nordlund‡, Michael Sundstrom†, Johan Welgelt‡, and Aled M. Edwards*[§]

*Structural Genomics Consortium, University of Toronto, 100 College Street, Toronto, ON, Canada M5G 1L5; †Structural Genomics Consortium, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom; ‡Structural Genomics Consortium, Karolinska Institutet, KI Scheeles vaeg 2 A1:410, 17177 Stockholm, Sweden







~10 frag
Candidates for elaboration



X-ray crystallography

Target engagement in cells: cellular thermal shift assays (CETSA)

Monitor levels of soluble proteins



compound treatment
in cells

heating and cooling


lyse cells

separation
(optional)


detection

Anticipated results from CETSA assays

T_{agg} curve



ITDRF curves




IsoThermal Dose Response Fingerprint
'apparent potencies' at single temp


Real results from CETSA assays

thymidylate synthase drugs in K562 cells

T_{agg} curve




ITDRF curves at 50 °C



quadruplicate data from one independent experiment

CETSA for high-throughput screening



CETSA for target identification of drugs

Cell Chemical Biology
Minireview

Small-Molecule Target Engagement in Cells

Marc Schürmann,¹ Petra Janning,¹ Slava Ziegler,¹ and Herbert Waldmann^{1,2,*}

¹Department of Chemical Biology, Max Planck Institute of Molecular Physiology, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany


²Technical University Dortmund, Department of Chemistry and Chemical Biology, Otto-Hahn-Strasse 6, 44227 Dortmund, Germany

*Correspondence: herbert.waldmann@mpi-dortmund.mpg.de

<http://dx.doi.org/10.1016/j.chembiol.2016.03.008>

Monitoring how, when, and where small molecules engage their targets inside living cells is a critical step in chemical biology and pharmacological research, because it enables compound efficacy and confirmation of mode of action to be assessed. In this mini-review we summarize the currently available methodologies to detect and prove direct target engagement in cells and offer a critical view of their key advantages and disadvantages. As the interest of the field shifts toward discovery and validation of high-quality agents, we expect that efforts to develop and refine these types of methodologies will also intensify in the near future.

Workflow for novel drug target identification




MIT News

ON CAMPUS AND AROUND THE WORLD

Browse

or

Search



Alveolar rhabdomyosarcoma, a soft tissue cancer

Image: Michael Bonert/Wikimedia Commons

Taking a moonshot at a rare childhood cancer

Team of researchers including MIT Professor Angela Koehler obtains \$5.8 million grant to study fusion-positive alveolar rhabdomyosarcoma.

CANCER MOONSHOT



 Duke Cancer Institute

Fusion Oncoproteins in Childhood
Cancers Consortium



 University of
Zurich ^{UZH}




 BROAD
INSTITUTE

 NATIONAL
CANCER
INSTITUTE

PAX3-FOXO1



pathognomic fusion in alveolar rhabdomyosarcoma



PAX3-FOXO1

pathognomic fusion in alveolar rhabdomyosarcoma
 pathognomic fusion in alveolar rhabdomyosarcoma



SMM screening data for PAX3-FOXO1 from cell lysates




PAX3-FOXO1

pathognomic fusion in alveolar rhabdomyosarcoma

SMM screening data for PAX3-FOXO1 from cell lysates



PAX3-FOXO1, FOXO1 CETSA



Our path to finding ligands - lectures

2/5/20	Lecture 1	Intro to chemical biology: small molecules, probes, and screens
2/11/20	Lecture 2	Our protein target: TDP-43
2/13/20	Lecture 3	Small molecule microarrays
2/18/20	No Lecture	
2/20/20	Lecture 4	Quantitative evaluation of protein-ligand interactions
2/25/20	Lecture 5	A ligand discovery vignette: sonic hedgehog
2/27/20	Lecture 6	Engineering transcriptional responses with a small molecule
3/3/20	Lecture 7	Wrap up discussion: suggestions for how to report your findings